Therapeutic opportunities for lenalidomide in non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Nathan H. Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing clinical trials that are investigating the use of lenalidomide, an immunomodulatory drug, as monotherapy or in combination for the treatment of different subtypes of non-Hodgkin lymphoma.

Share this video  
3rd October 2015